225 related articles for article (PubMed ID: 31045597)
1. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease.
Scarpignato C; Hunt RH
Curr Opin Gastroenterol; 2019 Jul; 35(4):344-355. PubMed ID: 31045597
[TBL] [Abstract][Full Text] [Related]
2. Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease.
Ramani A; Merchant A; Cash BD
Eur J Clin Pharmacol; 2023 Aug; 79(8):1023-1029. PubMed ID: 37344679
[TBL] [Abstract][Full Text] [Related]
3. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
Inatomi N; Matsukawa J; Sakurai Y; Otake K
Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
[TBL] [Abstract][Full Text] [Related]
4. Tegoprazan to treat gastroesophageal reflux disease.
Mermelstein J; Mermelstein AC; Chait MM
Drugs Today (Barc); 2020 Nov; 56(11):715-721. PubMed ID: 33332479
[TBL] [Abstract][Full Text] [Related]
5. Acid suppression therapy: where do we go from here?
Scarpignato C; Pelosini I; Di Mario F
Dig Dis; 2006; 24(1-2):11-46. PubMed ID: 16699262
[TBL] [Abstract][Full Text] [Related]
6. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
7. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
8. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
[TBL] [Abstract][Full Text] [Related]
9. Gastrointestinal pharmacology: practical tips for the esophagologist.
Scarpignato C; Sloan JA; Wang DH; Hunt RH
Ann N Y Acad Sci; 2020 Dec; 1481(1):90-107. PubMed ID: 32822080
[TBL] [Abstract][Full Text] [Related]
10. Potassium-competitive acid blockers and proton-pump inhibitors for healing of erosive esophagitis: a systematic review and network meta-analysis.
Liu Y; Gao Z; Hou X
Therap Adv Gastroenterol; 2024; 17():17562848241251567. PubMed ID: 38903448
[TBL] [Abstract][Full Text] [Related]
11. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.
Andersson K; Carlsson E
Pharmacol Ther; 2005 Dec; 108(3):294-307. PubMed ID: 16000224
[TBL] [Abstract][Full Text] [Related]
12. Potassium-competitive acid blockers and gastroesophageal reflux disease.
Leowattana W; Leowattana T
World J Gastroenterol; 2022 Jul; 28(28):3608-3619. PubMed ID: 36161043
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic treatment of GERD: Where we are now, and where are we going?
Scarpignato C; Hongo M; Wu JCY; Lottrup C; Lazarescu A; Stein E; Hunt RH
Ann N Y Acad Sci; 2020 Dec; 1482(1):193-212. PubMed ID: 32935346
[TBL] [Abstract][Full Text] [Related]
14. Vonoprazan fumarate for the management of acid-related diseases.
Martinucci I; Blandizzi C; Bodini G; Marabotto E; Savarino V; Marchi S; de Bortoli N; Savarino E
Expert Opin Pharmacother; 2017 Aug; 18(11):1145-1152. PubMed ID: 28657473
[TBL] [Abstract][Full Text] [Related]
15. Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors.
Shibli F; Kitayama Y; Fass R
Curr Gastroenterol Rep; 2020 Mar; 22(4):16. PubMed ID: 32185589
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
[TBL] [Abstract][Full Text] [Related]
17. Proton pump inhibitors in the management of gastroesophageal reflux disease.
Hrelja N; Zerem E
Med Arh; 2011; 65(1):52-5. PubMed ID: 21534455
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of potassium-competitive acid inhibitors in the treatment of gastroesophageal reflux: a systematic review and meta-analysis.
Zhou X; Duan H; Li Q; Wang Q; Sun X
Scand J Gastroenterol; 2024 Jul; 59(7):788-797. PubMed ID: 38741565
[TBL] [Abstract][Full Text] [Related]
19. Clinical Characterization of Vonoprazan-Refractory Gastroesophageal Reflux Disease.
Hamada S; Ihara E; Ikeda H; Muta K; Ogino H; Chinen T; Tanaka Y; Ogawa Y
Digestion; 2021; 102(2):197-204. PubMed ID: 31578027
[TBL] [Abstract][Full Text] [Related]
20. Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations.
Savarino E; Martinucci I; Furnari M; Romana C; Pellegatta G; Moscatelli A; Bodini G; Marabotto E; Savarino V; de Bortoli N; Blandizzi C
Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1333-1341. PubMed ID: 27428571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
